CXCR3 and renal cell carcinoma: In renal cell carcinoma (RCC), it was reported that high‐dose IL‐2 treatment in 20 patients elevated the plasma levels of CXCR3 ligands (CXCL9, CXCL10, and CXCL11), sequentially, forming an angiostatic environment 110.